Clinical Trials on Moderate to Severe Rheumatoid Arthritis

Total 9205 results

Fresenius Kabi SwissBioSim GmbH

Completed

MSB11022 in Moderate to Severe Rheumatoid Arthritis (Auriel-RA)

Moderate to Severe Rheumatoid Arthritis

Bulgaria, United Kingdom, Hungary, Czechia, Poland, Germany
ImmuneMed, Inc.

Not yet recruiting

A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Moderate to Severe Rheumatoid Arthritis

Netherlands
Amgen

Terminated

Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab (ROCkIES)

Moderate to Severe Rheumatoid Arthritis

United States, Canada, Puerto Rico
AbbVie (prior sponsor, Abbott)
University Health Network, Toronto

Completed

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (REACH)

Moderate-to-severe Rheumatoid Arthritis
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis

Moderate to Severe Active Rheumatoid Arthritis

China
Synta Pharmaceuticals Corp.

Completed

A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

Active, Moderate to Severe Rheumatoid Arthritis

Netherlands
Shanghai Henlius Biotech

Completed

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

Moderately to Severely Active Rheumatoid Arthritis

China
Biosplice Therapeutics, Inc.

Completed

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

Moderate to Severe Osteoarthritis

United States
RemeGen Co., Ltd.

Terminated

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Moderate and Severe Rheumatoid Arthritis

China
RemeGen Co., Ltd.

Completed

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Moderate and Severe RheumatoId Arthritis

China
Beer, Kenneth R., M.D., PA
Medicis Pharmaceutical Corporation

Completed

Upper Facial Remodeling With Perlane-L and Dysport (DPL-2010)

Mild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital Rhytids

United States
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Moderate and Severe Active Rheumatoid Arthritis | Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Moderately to Severely Active Crohn's Disease

United States
Aqpha Medical B.V.

Not yet recruiting

Safety and Performance of PTMC Dermal Filler

Moderate to Severe Nasolabial Fold
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
EuBiologics Co.,Ltd

Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Moderate to Severe Glabellar Lines

Korea, Republic of
Allergan

Completed

Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds

Moderate to Severe Nasolabial Folds

Germany, Netherlands
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Moderate to Severe Glabellar Line

Korea, Republic of
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Croma-Pharma GmbH

Completed

SAVINO (Saypha® Volume LIdocaine in Nasolabial FOlds)

Moderate to Severe Nasolabial Folds

Austria
Allergan

Completed

A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds

Moderate to Severe Nasolabial Folds

United States
Merz North America, Inc.

Completed

Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit

Moderate to Severe Midface Volume Deficit

Canada
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Moderate to Severe Glabellar Frown Lines

United States, Canada
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States
Merz Aesthetics GmbH
Merz Pharmaceuticals GmbH

Completed

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States, Germany
Croma-Pharma GmbH

Active, not recruiting

Saypha® VOLUME Lidocaine for Midface Augmentation (VOLIDO)

Moderate to Severe Midface Volume Deficit

United States
Allergan

Completed

JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines

Patients With Moderate to Severe Perioral Lines

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Terminated

Explore Efficacy of FMT Treating Childhood ASD Patients

ASD Accompanied by Moderate to Severe Gastrointestinal Symptoms

China
Merz North America, Inc.

Completed

Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Moderate to Severe Nasolabial Folds

Correction of Moderate to Severe Nasolabial Folds (NLFs)

China
Merz North America, Inc.

Completed

Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Nasolabial Folds in China

Correction of the Moderate to Severe Nasolabial Folds

China
Astellas Pharma Europe Ltd.

Completed

A Survey About Trade-offs When Choosing Menopause Treatments

Moderate to Severe Vasomotor Symptoms

United Kingdom
Kythera Biopharmaceuticals

Completed

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Kythera Biopharmaceuticals

Completed

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Pfizer

Completed

Pharmacokinetics Study of ALO-02 and OxyContin

Management of Moderate to Severe Pain

United States
Merz North America, Inc.

Completed

Evaluation of Pain With Belotero® Balance With Integral Lidocaine for Correction of the Nasolabial Folds

Correction of Moderate to Severe Nasolabial Folds

United States
QRxPharma Inc.

Completed

Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain

Acute Moderate to Severe Pain

United States
OrthoTrophix, Inc

Completed

A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees

Mild to Moderate Knee OA

United States
Merck Sharp & Dohme LLC

Terminated

A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)

Women | Moderate to Severe Vasomotor Symptoms in Postmenopausal
Egalet Ltd

Completed

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Moderate-to-severe Chronic Noncancer Pain

United States
Janssen Pharmaceutica

Withdrawn

A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain

Moderate to Severe Acute Non-Cancer Pain
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

United States
BioPharmX, Inc.

Completed

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

Moderate to Severe Papulopustular Rosacea

United States
Janssen Pharmaceutica

Withdrawn

A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

Moderate to Severe Chronic Non-cancer Pain
KoBioLabs
Novotech (Australia) Pty Limited

Completed

Study of Multiple Ascending Dose of KBL693 in Healthy Participants

Moderate to Severe Asthma

Australia
Abbott

Completed

Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain

Moderate to Severe Chronic, Non-malignant Pain

United States
Mundipharma Research GmbH & Co KG

Completed

A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain

Subjects With Moderate to Severe, Chronic Nonmalignant Pain
Pfizer

Recruiting

Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)

Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Active Moderate to Severe Rheumatoid Arthritis

Korea, Republic of

3

Subscribe